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Abstract
Objective: Many people living with HIV in sub-Saharan Africa desire biological children. Implementation of HIV prevention
strategies that support the reproductive goals of people living with HIV while minimizing HIV transmission risk to sexual
partners and future children requires a comprehensive understanding of pregnancy in this population. We analyzed
prospective cohort data to determine pregnancy incidence and predictors among HIV-positive women initiating
antiretroviral therapy (ART) in a setting with high HIV prevalence and fertility.
Methods: Participants were enrolled in the Uganda AIDS Rural Treatment Outcomes (UARTO) cohort of HIV-positive
individuals initiating ART in Mbarara. Bloodwork (including CD4 cells/mm3, HIV viral load) and questionnaires (including
socio-demographics, health status, sexual behavior, partner dynamics, HIV history, and self-reported pregnancy) were
completed at baseline and quarterly. Our analysis includes 351 HIV-positive women (18–49 years) who enrolled between
2005–2011. We measured pregnancy incidence by proximal and distal time relative to ART initiation and used multivariable
Cox proportional hazards regression analysis (with repeated events) to identify baseline and time-dependent predictors of
pregnancy post-ART initiation.
Results: At baseline (pre-ART initiation), median age was 33 years [IQR: 27–37] and median prior livebirths was four [IQR: 2–
6]. 38% were married with 61% reporting HIV-positive spouses. 73% of women had disclosed HIV status to a primary sexual
partner. Median baseline CD4 was 137 cells/mm3 [IQR: 81–207]. At enrolment, 9.1% (31/342) reported current pregnancy.
After ART initiation, 84 women experienced 105 pregnancies over 3.8 median years of follow-up, yielding a pregnancy
incidence of 9.40 per 100 WYs. Three years post-ART initiation, cumulative probability of at least one pregnancy was 28%
and independently associated with younger age (Adjusted Hazard Ratio (AHR): 0.89/year increase; 95%CI: 0.86–0.92) and HIV
serostatus disclosure to primary sexual partner (AHR: 2.45; 95%CI: 1.29–4.63).
Conclusions: Nearly one-third of women became pregnant within three years of initiating ART, highlighting the need for
integrated services to prevent unintended pregnancies and reduce periconception-related risks for HIV-infected women
choosing to conceive. Association with younger age and disclosure suggests a role for early and couples-based safer
conception counselling.
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Introduction
In sub-Saharan Africa, the majority of new HIV infections
occur in women of reproductive age [1]. Studies in North America
[2,3], Europe [4,5,6], and sub-Saharan Africa
[7,8,9,10,11,12,13,14,15] consistently report that HIV-infected
women and men desire children. HIV-uninfected individuals who
seek to conceive with an HIV-infected partner risk acquiring HIV.
If conception does occur, pregnancy itself is associated with
increased risks of HIV acquisition and transmission [16,17,18].
HIV-infected women and men who desire biological children
require strategies to protect at-risk partners and future children
from infection [13,19,20]. Antiretroviral treatment for the infected
partner [21], topical or systemic pre-exposure prophylaxis for the
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uninfected partner [22,23,24,25], and sex without condoms
limited to peak fertility offer effective safer conception strategies.
In addition, sperm processing and insemination for male-infected
couples [26,27], and home insemination [28] and/or male
circumcision [29,30,31] for female-infected couples reduce sexual
transmission risk for HIV-serodiscordant couples [32,33]. When
HIV-positive individuals do not desire children, effective contra-
ception is crucial to prevent unintended and/or unwanted
pregnancies [34,35,36].
Successful translation of HIV-prevention strategies that ac-
knowledge the reproductive goals and rights of people living with
HIV [37,38,39,40] requires a comprehensive understanding of
pregnancy incidence and predictors among HIV-infected and at-
risk women. These data are critical to estimate size, characteristics,
and needs of priority target populations to support safer
conception and contraception, maternal and child health, and
HIV treatment and care programs [10,41,42].
Uganda is an important setting in which to investigate
pregnancy incidence given high fertility rates (total fertility
rate = 6.7 births per women [43]), endemic HIV (adult HIV
prevalence = 6.7% [1]), and expanding antiretroviral therapy
coverage (47% of people eligible for treatment [44]).
The primary objective of this prospective study was to estimate
pregnancy incidence and assess baseline and time-updated
predictors of pregnancy among reproductive-aged women en-
rolled in a cohort of HIV-positive individuals initiating ART in a
rural region of Uganda.
Methods
Study Setting
Mbarara is a rural setting (population 83,700) located approx-
imately 265 kilometres southwest of Kampala. Adult HIV
prevalence in the region is estimated at 10% [45]. The Mbarara
University HIV clinic, called the Immune Suppression Syndrome
(ISS) clinic, is situated within the Mbarara Regional Referral
Hospital. The clinic has served more than 18,000 patients since it
opened in 1998 and offers comprehensive HIV care services,
including ART, at no cost to patients. ART is provided through
the Ugandan Ministry of Health with support from the President’s
Emergency Plan for AIDS Relief (PEPFAR), the Global Fund, and
the Family Treatment Fund [46].
Study Participants
Study participants were enrolled in the Uganda AIDS Rural
Treatment Outcomes (UARTO) cohort study, which was initiated
in July 2005 with the primary objective of determining predictors
of virologic failure and antiretroviral resistance. Participants were
recruited from treatment-naı¨ve patients initiating ART at the HIV
clinic. Clinic patients who were at least 18 years old and living
within 60 kilometers of the clinic were eligible to enroll in the
study. At the time of this analysis, 500 individuals were enrolled in
UARTO and 94% initiated ART within four days of enrolment.
The loss-to-follow-up rate (participants for whom we were unable
to confirm vital status after.= 180 days without cohort follow-up)
among UARTO participants was 2% at one year and 5% at two
years. For this analysis of pregnancy incidence, the sample was
restricted to female UARTO participants aged 18–49 years.
Over the cohort follow-up period, national antiretroviral
treatment guidelines were updated twice. Current (2009) guide-
lines recommend treatment for HIV-infected adults with CD4 cell
count below 250 cells/mm3, or below 350 cells/mm3 for those
with tuberculosis, pregnancy, or WHO stage III or IV disease
[47]. Guidelines for participants who initiated treatment prior to
2009 recommended ART initiation at CD4,200 cells/mm3 or
WHO Stage IV disease [48,49].
Data Collection
UARTO participants completed a baseline interview and
phlebotomy. They were subsequently scheduled for quarterly
follow-up interviews and phlebotomy, concurrent with their
scheduled clinic visits. Standardized interviewer-administered
questionnaires detailed demographics, mental and physical health,
sexual risk behaviour, and partner dynamics including partner
testing and HIV status. Incident pregnancies (and pregnancy
outcomes) were assessed quarterly via female participants’ self-
report. Interviews took 35–50 minutes to complete and were
conducted by trained interviewers fluent in English and Runyan-
kole, the dominant local language.
This analysis includes data from participants enrolled from June
2005 and followed-up through December 2011.
Measures
The primary outcome was self-reported pregnancy at baseline
and over the follow-up period (i.e., post ART-initiation), including
both first and recurrent pregnancies. Incidence was computed
using standard person-time methods. We applied the following
rules to calculate woman-years ‘at risk’ for pregnancy: (1) Among
women who reported pregnancy at baseline, time at risk
commenced upon the first subsequent visit where they reported
no longer being pregnant; (2) Women who became pregnant
during follow-up were censored upon their first visit reporting the
pregnancy and uncensored upon their first visit reporting no
longer being pregnant; (3) Women who did not become pregnant
were censored at the end of the follow-up period; and (4) Women
who reported sterilization (tubal ligation or hysterectomy) were
censored at baseline or, if during follow-up, upon reported date of
the procedure.
We examined the association of incident pregnancy subsequent
to ART initiation with baseline and time-updated variables,
identified as covariates of pregnancy incidence in previous studies
[8,10,42,50,51,52,53,54,55]. Baseline variables included socio-
demographic characteristics (including age, education, employ-
ment, household income, and marital status), reproductive history
(including parity), and clinical history (including time since HIV
diagnosis, time on ART, AIDS defining illnesses, CD4 cell count
at enrolment, and body mass index (BMI)). Time-updated
variables were measured quarterly and included CD4 cell count,
HIV viral load ,400 copies/mL, depression (measured using a
modified version of the Hopkins Symptom Check List and a cut-
off of $1.75 as indicative of clinical depression) [56,57,58], the
Medical Outcomes Study HIV Health Survey (MOS-HIV)
Physical Health and Mental Health Summary scores (scored on
a 0–100 scale, where a higher score indicates better health)
[59,60], sexual activity in the previous three months, and
disclosure of HIV status to primary sexual partner. ‘Disclosure
to primary sexual partner’ was included as a time-updated
variable, which combined information on currently having a
primary sexual partner (including spouse or regular partner) and
disclosure of HIV status to that partner. This yielded a three-level
variable including, (i) having disclosed HIV serostatus to a primary
sexual partner; (ii) not having disclosed to a primary sexual
partner; or (iii) not having a primary sexual partner (disclosure not
applicable). In longitudinal analyses, HIV serostatus disclosure was
time-updated based on changes in relationship status.
We also report pregnancy outcomes, based on participant self-
report. The outcome categories include live birth or ‘‘stillbirth/
miscarriage/termination’’ – the latter category includes three
Pregnancy Incidence after ART Initiation in Uganda
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possible outcomes asked as one composite outcome measure in the
interviews.
Statistical Analyses
Baseline characteristics of women with and without pregnancies
subsequent to ART initiation were compared using Wilcoxon rank
Table 1. Baseline characteristics of female UARTO participants aged 18–49 years by pregnancy after ART initiation1.
Overall (n = 351)
n (%) or median
(IQR)
Pregnancy after ART
initiation
(n =84)
n (%) or median (IQR)
No pregnancy after ART
initiation
(n =230)
n (%) or median (IQR) p-value
Median follow-up (years) 3.8 (2.4–4.6) 4.1 (2.7–4.7) 4.0 (2.7–4.7) 0.891
Socio-demographic characteristics
Median Age (years) 33 (27–37) 28 (24–33) 35 (30–39) ,0.001
Employed 240 (68%) 47 (56%) 165 (72%) 0.020
Education: Post- primary school 82 (23%) 16 (19%) 58 (25%) 0.623
Median monthly household income
(UGX)2
30,000 (10,000–60,000) 30,000 (10,000–54,000) 30,000 (10,000–80,000) 0.859
Marital Status
Married3 133 (38%) 45 (54%) 69 (30%) ,0.001
Never married 26 (7%) 10 (12%) 15 (7%)
Widowed 89 (26%) 9 (11%) 74 (32%)
Divorced 101 (29%) 20 (24%) 70 (31%)
Median # livebirths 4 (2–6) 4 (2–5) 4 (3–6) 0.088
Clinical status characteristics
Median time between HIV diagnosis
and ART initiation (months)
14 (4–36) 13 (5–25) 15 (4–39) 0.245
Ever had AIDS Defining Illness 174 (50%) 42 (50%) 115 (50%) 0.797
BMI (kg/m2) 0.567
,18.5 42 (12%) 10 (12%) 24 (10%)
[18.5–25) 238 (70%) 62 (74%) 163 (70%)
25 or more 59 (17%) 12 (14%) 43 (18%)
Median BMI (kg/m2) 21 (20–24) 22 (20–24) 21 (20–25) 0.787
Depression4 127 (36%) 32 (38%) 84 (37%) 0.793
Median CD4 cells/mm3 137 (81–207) 154 (88–230) 137 (87–199) 0.219
Virally suppressed (,400 copies/mL) 15 (4%) 2 (2%) 1 (,1%) 0.770
MOS-HIV Mental Health Summary
score
52 (44–57) 52 (41–57) 51 (45–56) 0.790
MOS-HIV Physical Health Summary
score
53 (44–59) 55 (46–59) 53 (43–58) 0.080
Sexual behaviour characteristics
Sex in the past 3 months 155 (44%) 55 (65%) 82 (36%) ,0.001
# of sexual partners in past 3 months5 0.242
1 148 (95%) 54 (98%) 76 (93%)
2+ 7 (5%) 1 (2%) 6 (7%)
Spouse HIV-positive6 81 (61%) 29 (64%) 39 (57%) 0.280
Spouse on ART7 39 (48%) 10 (34%) 22 (56%) 0.090
HIV serostatus disclosed to primary
partner8
111 (73%) 46 (84%) 51 (65%) 0.015
1351 women had enrolment information and are counted in the ‘Overall’ column. 314 had one or more follow-up visits (i.e., 37 women are excluded from the following
two columns assessing pregnancy post ART initiation).
2UGX is the currency symbol for Ugandan Shillings. 30,000 UGX , $12.20 USD (conversion rate: 1 USD= 2,458 UGX).
3Married or living as married, as per self-report.
4Depression was screened using the Hopkins Symptom Check List modified for use among people living with HIV with a cut-off of $1.75 indicating depression.
5Restricted to n = 155 who reported sex in the past 3 months (55 among those with pregnancy and 82 among those without pregnancy.).
6Restricted to n = 133 who reported being currently married (45 among those with pregnancy, 69 among those without pregnancy.).
7Restricted to n = 81 women with an HIV-positive spouse (29 among those with pregnancy, 39 among those without pregnancy.).
8Restricted to n = 151 who reported having a spouse or regular sexual partner (55 among those with pregnancy, 79 among those without pregnancy.).
doi:10.1371/journal.pone.0063411.t001
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sum test for continuous variables and Fisher’s exact test for
categorical variables.
We computed baseline pregnancy prevalence (all pregnancies
reported at or within 12 months prior to cohort enrolment),
cumulative incidence of pregnancy, and pregnancy outcome post
ART-initiation. Pregnancy incidence was calculated using person-
time methods and is reported as number of pregnancies per 100
woman-years (WYs) of follow-up. Time between cohort enrolment
to pregnancy or end of follow-up period was calculated for each
participant. We present data on overall pregnancy incidence as
well as pregnancy incidence (overall and first pregnancy) within
specified time intervals to distinguish between proximate and distal
associations between ART initiation and pregnancy incidence.
Kaplan-Meier curves display trends in pregnancy incidence
over time stratified by key baseline characteristics, including age,
marital status, and HIV serostatus disclosure to primary sexual
partner. Log-rank and likelihood ratio tests were used to test
differences in curves by predictor variable strata.
We modeled repeated events in a survival analysis with time-
dependent covariates using Cox proportional hazards regression to
identify independent predictors of pregnancy subsequent to ART
initiation. The modified sandwich estimator was used to account
for repeated measures among women with more than one
pregnancy during follow-up [61]. Follow-up time began at
treatment initiation or at first non-pregnant visit for women who
were pregnant at treatment initiation (i.e., baseline). After testing
for co-linearity and interactions, variables with significant associ-
ation with pregnancy in the bivariate analysis were considered for
the full model to obtain the relative contribution of each covariate,
expressed as an adjusted hazard ratio (AHR) with a 95%
confidence interval. Model selection was achieved by minimizing
the Akaike information criterion (AIC) while maintaining p-values
for covariates below 0.20 [62]. All statistical tests were 2-sided and
were considered significant at a= 0.05. Data were analyzed with
SAS version 9.3 [63].
Ethical Statement
All participants provided voluntary, written informed consent at
study enrolment. All procedures were approved by the Institu-
tional Ethics Review Board of Mbarara University of Science and
Technology (MUST), the Uganda National Council on Science
and Technology (UNCST), Partners Human Research Commit-
tee, and the Research Ethics Board of Simon Fraser University.
Results
Baseline Characteristics
351 women aged 18–49 years with baseline data were eligible
for this study. Analysis of incident pregnancy and predictors was
restricted to 314 women with at least one follow-up visit, who
contributed 1117.6 woman-years (WYs) of follow-up with a
median follow-up time of 3.8 years (IQR: 2.4–4.6).
Median age was 33 years (IQR: 27–37), 23% had more than a
primary school education, 68% were employed, and median
monthly household income was 30,000 (IQR: 10,000–60,000)
Ugandan Shillings (,$12 USD). Thirty-eight percent of women
were currently married or living as married. Of 133 married
women, 61% reported an HIV-positive spouse, of whom 48%
were on ART. Median number of prior live births was 4 (IQR: 2–
6) (Table 1).
Forty-four percent of women reported sexual activity in the
prior three months, of whom 95% reported only one partner and
5% reported two or more partners. Among women reporting a
spouse and/or regular sexual partner, 73% had disclosed HIV
status to this partner.
Median time between HIV diagnosis and ART initiation was 14
months (IQR: 4–36 months), 50% reported ever having an AIDS-
defining illness, and median body mass index (BMI) was 21 kg/m2
(IQR: 20–24). Overall median CD4 cell count at enrolment was
137 cells/mm3 (IQR: 81–207), and, consistent with national
guidelines to initiate therapy for pregnant women, was higher
among women pregnant at enrolment (226 cells/mm3 (IQR: 174–
397)) compared with women not pregnant at enrolment
(135 cells/mm3 (IQR: 81–202); p,0.0001). Thirty-six percent of
women screened positive for depression at baseline. Median
MOS-HIV Physical Health and Mental Health Summary scores
were 52 (IQR: 44–57) and 53 (IQR: 44–59), respectively.
Pregnancy Prevalence and Outcomes at Baseline
Among 342 women with baseline data, 23 (6.7%) women
reported pregnancy within 12 months prior to enrolment and 31
(9.1%) reported pregnancy at enrolment. The 31 baseline
pregnancies resulted in 24 live births, two terminations/miscar-
riages/or stillbirths, and four women remained pregnant at
censoring (1 missing outcome).
Of the 31 women pregnant at ART initiation, 63% reported
HIV diagnosis more than 9 months prior to enrolment. Thus, at
least 63% of the prevalent pregnancies occurred among women
who knew their positive HIV status prior to conception.
Incidence of Pregnancy after Initiation of ART
Among 314 women with at least one follow-up visit, 84 reported
pregnancy over the follow-up period. Of these women, 66
reported a single incident pregnancy, 15 reported two incident
pregnancies, and three women reported three incident pregnan-
cies, totalling 105 pregnancies over 1117.6 WYs of follow-up
(pregnancy incidence = 9.40 per 100 WYs; 95% CI: 7.68, 11.4).
The 105 pregnancies resulted in 57 live births (54%), 22
terminations/miscarriages/or stillbirths (21%), and 12 women
remained pregnant as of their most recent visit (11%) (14 missing
outcomes (13%)).
As shown in Figure 1, incidence of pregnancy (including first
and recurrent pregnancies) was higher with recent initiation of
ART. Incidence of first pregnancy peaked between 6–12 months
after ART initiation (15.2 pregnancies per 100 WYS (95% CI:
9.53, 23.0)), declined and stabilized between 12–36 months, then
decreased sharply 36 months after ART initiation (Table S1).
Recurrent pregnancies peaked between 24–30 months and again
at 48+ months after ART initiation. When first and recurrent
pregnancy incidence are combined, overall pregnancy incidence
peaked 6–12 months after ART initiation (15.5 pregnancies per
100 WYs (95% CI: 9.80, 23.2), dipped between 12–18 months,
and showed a second peak from 18 through 30 months. After 30
months, we observed a steep decline in pregnancy incidence until
48+ months, when pregnancy incidence rebounded slightly. As
shown in Figure 1, the higher overall incidence of pregnancy at
24–30 months and 48+ months was principally due to recurrent
pregnancies.
Probability of Pregnancy Over Time
By one, two, and three years post-ART initiation the overall
probability of pregnancy was 12%, 20%, and 28%, respectively
(Figure 2.a).
When stratifying by key baseline characteristics, for younger
women (less than 35 years of age, the peak childbearing years for
Ugandan women [43] (Figure 2.b), the probability of pregnancy
after ART initiation was 18%, 29%, and 42%, by years one, two,
Pregnancy Incidence after ART Initiation in Uganda
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and three respectively. Similarly, among women who were
married at baseline (Figure 2.c), the cumulative probability of
pregnancy by year three was 43%. Further, among women with a
regular sexual partner (spouse or otherwise) to whom they
disclosed their HIV status, the cumulative probability of
pregnancy by year three was 52%. As further shown in
Figure 2.d, disclosure showed a delayed effect on probability of
pregnancy as it was only associated with a higher incidence among
those pregnancies occurring 12 months after ART initiation.
Baseline and Time-updated Predictors of Pregnancy Post
ART-initiation
In the unadjusted analysis (Table 2), factors associated with an
increased risk of pregnancy after ART initiation included younger
age (time-updated) (hazard ratio (HR): 0.90 per 1 year increase in
age; 95% CI: 0.87–0.93), being married (HR: 1.93; 95% CI: 1.31–
2.83), having disclosed HIV status to a primary sexual partner
(time-updated) (HR: 1.90; 95% CI: 1.02–3.56), higher CD4 cell
count (time-updated) (HR: 1.21 per 100 cells/uL increase; 95%
CI: 1.03–1.40), and HIV diagnosis within 12–30 months of
initiating ART (versus .30 months) (HR: 1.97; 95% CI: 1.14–
3.41). Employed women had a lower risk of pregnancy after ART
initiation (HR: 0.56; 95% CI: 0.38–0.83).
In the adjusted model (Table 2), younger age and having
disclosed HIV status to primary sexual partner (both time-
updated) remained independently associated with pregnancy risk
(adjusted hazard ratio (AHR) = 0.89 per year increase in age; 95%
CI: 0.86–0.92 and AHR = 2.45; 95% CI: 1.29–4.63 among those
who disclosed compared with those who did not disclose).
As described in the methods, ‘Disclosure to a primary partner’
combines information regarding currently having/not having a
primary sexual partner (including spouse and/or regular partners)
and disclosure to that partner. The ‘N/A’ category denotes that
the woman does not currently have a regular sexual partner. In the
adjusted model, there was no statistically significant difference in
pregnancy risk between those without a primary sexual partner
and those with a primary sexual partner to whom they had not
disclosed HIV status, suggesting that the explanatory power of this
variable stems from the presence or absence of disclosure, beyond
the presence or absence of a primary sexual partner.
Discussion
In this study, we describe the incidence of pregnancy among
HIV-infected women initiating ART. Baseline pregnancy preva-
lence was 9% and pregnancy incidence was 9.40 per 100 WYs
during a median of 3.8 years of follow-up after initiation of ART.
By one, two, and three years after ART initiation, the overall
Figure 1. Incidence of overall and first pregnancy. Incidence of overall and first pregnancy (per 100 woman-years) by 6-month intervals post
ART initiation (in months) (n = 314).
doi:10.1371/journal.pone.0063411.g001
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cumulative probability of pregnancy in this cohort was 12%, 20%,
and 28%, respectively.
Among women reporting pregnancy at baseline, over one-third
were diagnosed with HIV during the pregnancy. The remaining
two-thirds became pregnant after knowing their HIV status but
before ART initiation. For these women, conception and
pregnancy were likely associated with increased risks of poor
health outcomes and of HIV transmission to sexual partners.
The observed pregnancy incidence of 9.40 pregnancies per 100
WYs is within the range of comparable regional studies of
reproductive-aged women initiating ART [10,42,64,65,66]. This
incidence is lower than that reported in studies employing
inclusion criteria that affect probability of pregnancy, including
younger age group [67] and non-use of injectable contraception
[41].
We cannot directly assess whether pregnancy incidence among
this cohort differs from HIV-infected women not on ART. A
retrospective study of pregnancy incidence among women
receiving HIV treatment and care at the referral clinic for this
cohort reported a similar pregnancy incidence (8.6 pregnancies
per 100 WYs) with no difference by ART use [68]. Other regional
studies enrolling HIV-positive ART-naı¨ve women have reported
similar [53] or higher [69,70,71] pregnancy incidence. A large
multi-country study found a lower incidence of subsequent
pregnancy among women initiating ART during pregnancy with
substantial variability in rates by individual country setting [42].
The recent results of the DART trial, which enrolled women
initiating ART in Uganda and Zimbabwe, similarly reported a
lower incidence of pregnancy (4.4 per 100 woman years [95% CI
4.0–4.9] [66].
The pregnancy incidence observed among UARTO partici-
pants is lower than for the general Ugandan population. The age-
specific fertility rate of women aged 30–34 years in Uganda is 24.8
births per 100 women [72] which, while not directly comparable,
is well above a pregnancy rate of 9.40 pregnancies per 100 WYs
found in this study. This is consistent with data that suggest HIV-
infected women have lower fertility than HIV-uninfected women
[73,74,75].
The pregnancy incidence observed in this and other studies,
coupled with estimates from the same site reporting that 85% of
HIV-positive women do not intend to become pregnant [12,76]
but have low rates of contraceptive use [77] and regional estimates
that most pregnancies among women with HIV are reported as
unplanned and/or unwanted [10,78] reinforces the need for
improved, comprehensive reproductive counselling that promotes
contraception to avoid unwanted pregnancies and safer concep-
tion for women who want pregnancy.
We observed that incidence of pregnancy varied with time since
ART initiation, with highest incidence in periods proximal to
ART initiation (with a peak in pregnancy incidence between 6–12
months) and lower incidence in periods distal to ART initiation.
Four years after ART initiation, we observed a resurgence in
pregnancy incidence, largely accounted for by recurrent pregnan-
cies. Other regional studies have reported an independent effect of
ART on increasing pregnancy incidence over time compared with
ART-naı¨ve women [10,41,42]. This is consistent with studies from
Figure 2. (a–d). Kaplan-Meier curves of probability of pregnancy. Kaplan-Meier curves of probability of pregnancy over time (n = 314).
Figure 2a. Overall. Figure 2b. Stratified by age. Figure 2c. Stratified by marital status. Figure 2d. Stratified by disclosure. Figure 2a. Probability of
pregnancy over time among HIV-positive women initiating ART. Figure 2b. Probability of pregnancy over time among HIV-positive women initiating
ART, stratified by age (,35 years vs. .= 35 years). Figure 2c. Probability of pregnancy over time among HIV-positive women initiating ART, stratified
by marital status (Currently married vs. not currently married). Figure 2d. Probability of pregnancy over time among HIV-positive women initiating
ART, stratified by disclosure of HIV status to primary partner (Non-disclosure vs. Disclosure vs. No primary partner (N/A)).
doi:10.1371/journal.pone.0063411.g002
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North America and Europe reporting an increase in pregnancy
and birth rates among HIV-positive women after widespread
availability of ART [51,54,79,80]. Whether increased pregnancy
incidence after ART is a result of biological (e.g., improved
fecundity) or behavioural change (e.g. improved sexual drive with
restored health, increased fertility intentions) is not well under-
stood but is likely due to a combination of factors [10,42,74,81,82].
These data underscore the need to incorporate comprehensive
reproductive counselling for women upon HIV diagnosis and prior
to ART initiation, rather than waiting and expecting women to
initiate discussions with healthcare providers once they intend to
become pregnant [67,83].
Independent, time-varying predictors of incident pregnancy in
this cohort include younger age and disclosure of HIV status to a
primary sexual partner. Younger age has been associated with
higher fertility desire [7,9,12,14,81,84], lower contraceptive use
[82], higher fecundity [85], strong societal and partner pressures
towards early and frequent childbearing [81], and higher incident
pregnancy in several studies of both HIV-positive women
[10,41,42,53] [66] and women in general [86].
As shown in Figure 2.b, among women under 35 years of age,
the probability of pregnancy within three years of ART initiation
was 42%, compared with 11% probability among women older
than 35. While all women of reproductive age are at risk for
pregnancy events and should receive routine counselling to discuss
reproductive goals and services to prevent unintended pregnancies
and reduce periconception-related HIV transmission risks, these
data suggests that younger women are a critical target population.
Interviews with pregnant HIV-positive women in Kampala
explored the complex role that HIV serostatus disclosure plays in
pregnancy decision-making [87]. Disclosure is a precondition for
encouraging a partner to engage in HIV risk reduction activities
for the purposes of conception or otherwise and has been positively
associated with partner HIV testing, increased care seeking,
alleviation of anxiety, improved communication, and higher
motivation to make plans for the future [88]. Women who
Table 2. Cox proportional hazard regression analysis of baseline and time-updated factors associated with pregnancy after ART-
initiation (n = 314).
Variable Unadjusted Hazard Ratio (HR) (95% CI) Adjusted Hazard Ratio (AHR) (95% CI)
Socio-demographic characteristics
Age (time-updated) 0.90 (0.87–0.93) 0.89 (0.86–0.92)
Employed: Yes vs. No 0.56 (0.38–0.83) –
Education: Post-primary school vs. less education 0.81 (0.54–1.20) –
Median monthly household income (per 10,000 UGX increase) 1.01 (0.99–1.02) –
Marital Status: Married vs. Not married 1.93 (1.31–2.83) `
Number of prior Live Births: –
4+ vs. ,4 0.88 (0.60–1.30)
2+ vs. 0–1 (as an alternate cut-off) 0.61 (0.37–1.01)
Clinical status characteristics
Months since HIV diagnosis
,12 vs. more than 30 1.34 (0.80–2.23) –
12–30 vs. more than 30 1.97 (1.14–3.41)
AIDS-defining Illness (ADI) at baseline 1.24 (0.82–1.88) –
BMI at baseline (kg/m2) 0.99 (0.94–1.05) –
Depression (time-updated) 1.14 (0.77–1.70) –
CD4 cell count (per 100 cells/uL) (time-updated) 1.21 (1.03–1.40) –
Viral suppression (time-updated) 1.70 (0.91–3.18) –
MOS-HIV Mental Health Summary score (time-updated) 0.99 (0.97–1.01) –
MOS-HIV Physical Health Summary score (time-updated) 1.02 (1.00–1.04) –
Sexual behaviour
Spouse HIV positive at baseline
Yes vs. No 0.95 (0.44–2.03) –
N/A vs. No 0.40 (0.18–0.86)
DK vs. No 0.74 (0.33–1.65)
Spouse on ART at baseline 0.71 (0.37–1.40) –
HIV serostatus disclosed to primary partner (time-updated)`
Yes vs. No 1.90 (1.02–3.56) 2.45 (1.29–4.63)
N/A vs. No 0.65 (0.34–1.24) 0.78 (0.41–1.50)
Notes:
`‘Disclosure to primary partner’ combines information between sex with regular partner (including spouse) and disclosure. The N/A category implies that the individual
does not have a regular sexual partner. Given collinearity between ‘Disclosure to primary partner’ and ‘marital status’, only ‘Disclosure to primary partner’ was included
in the final adjusted model.
doi:10.1371/journal.pone.0063411.t002
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disclose their status may encounter reduced societal and familial
expectations for childbearing [81] but rising community awareness
of the benefits of ART may increase pressure to conceive [89].
We observed that serostatus disclosure to the primary sexual
partner was a positive and independent predictor of incident
pregnancy, however, the effect was not observed until more than
one year after ART initiation. Pregnancy intention was not
measured in this study, however, the strong association with
partner disclosure may suggest that these later pregnancies were
wanted and/or planned, or discussed. Those pregnancies occur-
ring in the first year may be highly influenced by the biological and
behavioural changes observed with ART initiation and influencing
fertility as described above. However, pregnancies occurring more
than one-year after ART initiation might be less influenced by
those changes and we may be observing a shift to more planned,
intended pregnancies. The positive association between serostatus
disclosure and pregnancy suggests a role for couples-based safe
conception counselling in this population. More research is
required to better understand this dynamic relationship.
Spouse HIV-status showed no association with pregnancy.
Thirty-nine percent (39%) of women reported spouses of unknown
or negative HIV-status, leaving those men at high risk for
periconception or antepartum HIV-acquisition. Male partners
play a large role in conception decisions and, if HIV-negative, risk
HIV acquisition when seeking to conceive with an HIV-positive
partner [7,13,90]. Comprehensive reproductive counselling pro-
grams must include men.
Limitations of this study include use of self-report for pregnancy,
which likely led to an underestimate of the true incidence.
Pregnancies resulting in spontaneous abortion prior to detection
and pregnancies that were electively terminated may not have
been fully captured. Second, we did not have data on fertility
intention, pregnancy desire, or contraceptive use, which would
have implications for the most appropriate intervention. A higher
proportion of unplanned pregnancies would emphasize the need
for integrated family planning services including a range of
contraceptive options for women initiating ART, who may
experience restoration of fecundity. A higher proportion of
‘planned’ or ‘desired’ pregnancies would suggest a greater role
for periconception risk reduction strategies to minimize HIV
transmission risks. To address these limitations we have initiated a
reproductive health study within this cohort to collect these data
with the goal of understanding determinants of fertility intention,
behaviour, and pregnancy among HIV-affected couples to inform
the design of integrated bio-behavioural interventions to mitigate
HIV-transmission risk among couples who intend to have
children.
Conclusion
This study measured pregnancy incidence among HIV-positive
women initiating ART and followed over a five-year period. Our
findings that 9% were pregnant at ART initiation and that nearly
one-third experience pregnancy subsequent to ART initiation
highlight the need for integrated reproductive counselling and
services that prevent unintended pregnancies and reduce peri-
conception-related risks for HIV-positive women choosing to
conceive.
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